Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Ketek Will Return To FDA Advisory Committee Jan. 8

Executive Summary

FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29
Advertisement

Related Content

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis submits additional Ketek information
Aventis submits additional Ketek information
Antibiotic Trial Without Comparator Would Lower R&D Cost, Wyeth Exec Says
Antibiotic Trial Without Comparator Would Lower R&D Cost, Wyeth Exec Says
Ketek review scheduled
Aventis Ketek
Aventis Ketek CAP Resistance Claim Needs Larger Trials, Advisory Cmte. Says
Aventis Ketek CAP Resistance Claim Needs Larger Trials, Advisory Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS040712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel